Inspira Technologies Oxy B.H.N. Ltd. (IINN)
After hours:
| Previous close | 1.9000 |
| Open | 1.8900 |
| Bid | 1.8400 x 400 |
| Ask | 1.8800 x 400 |
| Day's range | 1.8360 - 1.9430 |
| 52-week range | 0.7610 - 2.4900 |
| Volume | |
| Avg. volume | 1,160,557 |
| Market cap | 32.684M |
| Beta (5Y monthly) | 2.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings date | 18 Mar 2024 - 22 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
PR NewswireInspira™ Receives CSA Certification of Compliance to U.S. Standards for the INSPIRA™ ART100
Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced that it has received the Canadian Standards Association (CSA) Certification of Compliance to U.S. standards for the INSPIRA ART100 device.
- PR Newswire
Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures
Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is proud to announce the signing of a collaboration term sheet (the "Term Sheet") with the Beilinson Hospital in Israel for the evaluation of its proprietary INSPIRA ART100 device (the "Device") in organ transplant procedures. This Term Sheet marks a significant advancement and opportunity for the Company in its technology being extended for use in additio
- PR Newswire
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, together with Ennocure MedTech Ltd. ("Ennocure"), announced results from their collaborative development of a proprietary bio-electronic treatment to prevent associated bloodstream infections in patients in intensive care units.
